Trial register facet
Trial records for Semaglutide — page 3
71 records for Semaglutide, of which 16 are published trials.
Showing 0 records on this page
Records
71 documents · page 3 of 3
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| STEP-3-ADHERENCEprogramme record | Semaglutide | Phase 3 | Reported | Observational | — | 2021 | Very low |
| STEP-4-DDIprogramme record | Semaglutide | Phase 1 | Reported | Randomised crossover | — | 2021 | Very low |
| STEP-1-OLEprogramme record | Semaglutide | Phase 3 | Reported | Single-arm open-label | — | 2021 | Very low |
| STEP-2-PKprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2021 | Very low |
| STEP-3-BIOMARKERprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| STEP-4-HEPATIC-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2021 | Very low |
| SUSTAIN-7 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, active-controlled | 1,201 | 2018 | High |
| SUSTAIN-7-BIOMARKERprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| SUSTAIN-7-ADHERENCEprogramme record | Semaglutide | Phase 3 | Reported | Observational | — | 2018 | Very low |
| SUSTAIN-7-OLEprogramme record | Semaglutide | Phase 3 | Reported | Single-arm open-label | — | 2018 | Very low |
| SUSTAIN-7-ELDERLYprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| SUSTAIN-7-RENAL-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2018 | Very low |
| SUSTAIN-1 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 388 | 2017 | High |
| SUSTAIN-1-QOLprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| SUSTAIN-1-REGIONAL-CNprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| SUSTAIN-1-REGIONAL-JPprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| SUSTAIN-1-BODY-COMPprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| SUSTAIN-1-DDIprogramme record | Semaglutide | Phase 1 | Reported | Randomised crossover | — | 2017 | Very low |
| SUSTAIN-6 | Semaglutide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 3,297 | 2016 | High |
| SUSTAIN-6-BODY-COMPprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2016 | Very low |
| SUSTAIN-6-REGIONAL-JPprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2016 | Very low |
| SUSTAIN-6-REGIONAL-CNprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2016 | Very low |
| SUSTAIN-6-QOLprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2016 | Very low |
page 3 of 3